Advertisement

Topics

Search Results for "April 2013 Update On Transvaginal Mesh Lawsuits"

17:35 EST 9th February 2016 | BioPortfolio

Matching Channels

Proliferation inducing ligand APRIL

Treatment of inflammatory and autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis and multiple sclerosis.

Abiraterone Acetate - Zytiga

On April 28, 2011, the US Food and Drug Administration (FDA) approved Zytiga (abiraterone acetate), for use in combination with prednisone for the second-line treatment of castration-resistant prost...

iBioLaunch

The iBioLaunch™ platform is a  proprietary gene expression technology that causes non-transgenic plants to rapidly produce high levels of target proteins.  The plants are easily and ...

Veregen

Veregen® is an ointment used to treat external genital warts. In the USA, Germany, Austria, Spain, Switzerland and Serbia, Veregen® is already marketed by our partners. Sales and marketing p...

Kinases Raf Inhibitors

The Ras-Raf-MEK-ERK (ERK) pathway is a logical therapeutic target because it represents a common downstream pathway for several key growth factor tyrosine kinase receptors which are often mutated or...

Matching News

C.R. Bard Settles 3,000 Mesh Cases for $200 Million

Victims of transvaginal mesh injuries earned another victory over device manufacturers. C.R. Bard agreed to pay $200 million to settle roughly 3,000 cases, concluding about 20 percent of remaining law...

J&J Agrees to Pay Over $120M to Settle Thousands of Mesh Lawsuits

Johnson & Johnson offered a large settlement to resolve its first big group of transvaginal mesh lawsuits, Bloomberg reported. The company agreed to settle as many as 3,000 cases for more than $12...

J&J Takes $12.5 M Hit in Philly Transvaginal Mesh Trial

Johnson & Johnson’s Ethicon unit took a multi-million dollar trial loss over its transvaginal mesh implant at the end of last year, and 2016 started off with the Food and Drug Administration...

Boston Scientific mesh verdict slashed to $10 million

NEW YORK (Reuters) - A Delaware judge on Friday said Boston Scientific should only have to pay $10 million to a woman originally awarded $100 million by a jury who found she was injured by transvagina...

C.R. Bard Pays $3.6MM in First Avaulta Transvaginal Mesh Case

HOUSTON, Nov. 18, 2015 /PRNewswire/ -- MT Services LLC, a Lawsuit Settlement News Reporting Company which operates http://www.lawsuitsettlementnews.com/, announced today that C.R. Bard finally pa...

Coloplast Increases Mesh Legal Budget by $448 million

Danish manufacturer Coloplast increased the transvaginal mesh litigation provision in its budget by 3 billion Danish crowns ($448 million). The provision is set aside to cover settlement and legal cos...

FDA Reclassifies Vaginal Mesh as a High-Risk Device

Already hounded by numerous lawsuits over adverse events, manufacturers have 30 months to prove the safety and effectiveness of these devices for transvaginal repair of pelvic organ prolapse. News ...

Transvaginal Mesh Lawsuit Settlement News: Coloplast Increases TVM Budget by $448MM

HOUSTON, Nov. 5, 2015 /PRNewswire/ -- MT Services LLC, a Lawsuit Settlement News Reporting Company which operates lawsuitsettlementnews.com, announced today that Coloplast has recently increased ...

Matching PubMed Articles

Transvaginal mesh in the media following the 2011 US food and drug administration public health notification update.

Prompted by patients' changing perceptions of transvaginal mesh, this study examines how mesh has been reported in the news following the 2011 US Food and Drug Administration (FDA) updated notificatio...

Management of complications of mesh surgery.

Transvaginal placements of synthetic mid-urethral slings and vaginal meshes have largely superseded traditional tissue repairs in the current era because of presumed efficacy and ease of implant with ...

3-year results of transvaginal cystocele repair with transobturator four-arm mesh: A prospective study of 105 patients.

To evaluate the long-term efficacy and safety of transobturator four-arm mesh for treating cystoceles.

Risks of transvaginal mesh may be associated with an increased risk of urinary retention and reintervention.

Reoperation After Robotic and Vaginal Mesh Reconstructive Surgery: A Retrospective Cohort Study.

Our primary objective was to compare reoperations after robotic-assisted sacrocolpopexy and transvaginal mesh for apical prolapse repair. Our secondary aim was to record perioperative complications af...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement